---
title: "Understanding the Market | XTALPI opened over 6% higher after reaching a $345 million platform strategic cooperation with Eli Lilly for AI-enabled bispecific antibodies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264537697.md"
description: "XTALPI opened more than 6% higher, and as of the time of writing, it has risen 6.05% to HKD 11.4, with a transaction volume of HKD 41.9461 million. XTALPI announced that its wholly-owned subsidiary Ailux has reached a multi-target strategic cooperation and platform licensing agreement with Eli Lilly worth USD 345 million, which includes tens of millions of dollars in upfront and milestone payments. This collaboration will accelerate the discovery and development of bispecific antibodies and promote research on the AI antibody development platform"
datetime: "2025-11-06T01:27:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264537697.md)
  - [en](https://longbridge.com/en/news/264537697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264537697.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264537697.md) | [繁體中文](https://longbridge.com/zh-HK/news/264537697.md)


# Understanding the Market | XTALPI opened over 6% higher after reaching a $345 million platform strategic cooperation with Eli Lilly for AI-enabled bispecific antibodies

According to Zhitong Finance APP, XTALPI (02228) opened over 6% higher, and as of the time of writing, it has risen by 6.05%, trading at HKD 11.4, with a transaction volume of HKD 41.9461 million.

In terms of news, XTALPI announced that its wholly-owned subsidiary Ailux has reached a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to USD 345 million, including tens of millions of dollars in upfront payments and recent milestone payments. Eli Lilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies (dual antibodies) across multiple therapeutic areas, while also utilizing its AI antibody research platform to expedite research on its internal pipeline. This marks another collaboration between XTALPI and Eli Lilly following their signing of a USD 250 million AI small molecule drug cooperation in 2023.

It is reported that Ailux is a macromolecule drug research and development platform that XTALPI has been focusing on since 2021, and it has experienced rapid development and commercial 成果转化 in the past two years. Ailux achieves precise AI antibody drug design and engineering through its combined wet and dry research and development model, effectively addressing the challenges of high costs and long cycles in drug discovery, helping pharmaceutical companies explore richer targeting mechanisms and differentiated drug development pathways. In the future, Ailux will also have the capability to advance various next-generation antibody drugs designed by AI to later clinical stages to secure more impactful major commercial collaborations

### Related Stocks

- [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md)
- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/en/news/281395595.md)
- [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/en/news/280952509.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/en/news/281311983.md)
- [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/en/news/281171668.md)
- [Traders Buy High Volume of Eli Lilly and Company Call Options (NYSE:LLY)](https://longbridge.com/en/news/281412176.md)